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Introduction. Polycystic ovary syndrome is a heterogeneous disorder characterized by 
hyperandrogenism, insulin resistance, metabolic disorders, anovulatory cycles and infertility, 
affecting 6% - 20% of women of reproductive age. At the same time, this syndrome represents 
about 75% of the causes of endocrine infertility and 95% of the causes of hirsutism.  
Aim of the study. The purpose of the study was to select the groups of drugs used in the 
treatment of polycystic ovary syndrome and to analyse their presence on the pharmaceutical 
market with argument of the rationality of use.  
Materials and methods. The specialized literature was analysed with the selection of the 
groups and drugs recommended in the pharmacotherapy of polycystic ovary syndrome with 
the argument of the pathophysiological mechanisms responsible for their effectiveness. Based 
on the study of the State Nomenclature of Medicines, were selected the groups of drugs present 
on the pharmaceutical market in the Republic of Moldova.  
Results. In the Republic of Moldova are registered metformin (oral antidiabetic biguanide) and 
combination medication (with glibenclamide, sitagliptin, vildagliptin), saxagliptin (oral 
antidiabetic, dipeptidyl-peptidase-IV inhibitor), letrozole (aromatase inhibitor), ciproterone, 
flutamide , finasteride (antiandrogen), clomiphene (estrogen receptor modulators), oral 
contraceptives (estrogen-progestin), spironolactone (aldosterone antagonist and antiandrogen), 
gonadotropins, myoinositol and simvastatin (hypolipemic statins). The use of oral antidiabetics 
is determined by the diminution of insulin resistance and metabolic effects that accompany the 
metabolic syndrome (obesity, dyslipidemias, hyperinsulinemia, hyperglycemia). 
Antiandrogenic preparations, aromatase inhibitors, spironolactone and oral contraceptives will 
contribute to the combat against hyperanderogenism and hirsutism. Hypolipidemic statins will 
result in decreased cholesterol synthesis and steroidogenesis with excessive testosterone 
synthesis. Gonadotropin drugs will be used for ovulation and pregnancy. Myoinositol and 
polyvitamin and mineral supplements will help correct metabolic disorders.  
Conclusions. The study established the presence of groups of drugs used in the treatment of 
polycystic ovary syndrome in the State Nomenclature of Medicines, which will influence the 
pathogenetic links of the disease.  
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Introduction. Migraine is a recurrent headache disorder affecting ∼15% of the population 
during the most productive periods of their lives, between the ages of 22 and 55 years. Chronic 
migraine is no longer considered a complication of migraine and is recognized in individuals 
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that had at least five attacks fulfilling criteria for migraine with/or without aura. This disorder 
affects 1,4-2,2% of the population and is associated with a higher headache impact in 
comparison with the episodic migraine. Medication overuse of acute analgesics often occurs 
with chronic migraine. In patients with migraine frequent intake of acute headache medication 
can increase the frequency and intensity of headache, causing a vicious circle of further intake 
of medication and increased attack frequency. Here is how the treatment can become the cause 
of another separate condition, known as medication-overuse headache.  
Aim of the study. To determine medication overuse of acute treatment in patients with chronic 
migraine and its impact to the severity of the disease.  
Materials and methods. In this study were included 36 patients with confirmed clinical 
diagnosis of chronic migraine who requested a consultation of a neurologist at the Institute of 
Neurology and Neurosurgery in Chisinau. The study was based on survey: self-report 
questionnaire with references to the medicamentous migraine treatment and Migraine patient 
assessment questionnaire from the National Clinical Protocol. A clinical analysis of the disease 
and medication intake were performed. The patients were separated in two groups: with and 
without medication overuse of acute treatment (medication overuse is diagnosed if a limit 
medication days per month is exceeded for ergotamines, triptans, opioids and combination 
drugs ≥10 days per month, and for simple analgesics ≥15 days per month, both for longer than 
3 months), based on the results of two questionnaires. Student-T test was chosen as statistical 
criteria for this research.  
Results. We found that patients with medication overuse of acute treatment have a significantly 
more severe clinical signs of the disease. We compared the following clinical outcomes: 
number of days with headache per month and intensity of headache. In case of medication 
abuse we found higher values on two parameters: frequency (p<0.0001) and intensity 
(p=0.0016) of headache per month.   
Conclusions. On conclusion, the analysis of our data support the concept that medication 
overuse is the reason for the development of more severe clinical signs in patients with existing 
primary headache disorder. Patients who managed correctly their migraine attacks have 
moderated clinical signs.  
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Introduction. Numerous recent studies show that misuse of stimulants by individuals without 
ADHD (Attention Deficit Hyperactivity Disorder) has increased over last years, in order to 
enhance cognitive performance. This is especially popular among students. Hence, the need to 
assess the effects of methylphenidate on healthy brain (without ADHD), as well as the 
associated adverse reactions, arises.  
Aim of the study. To evaluate the prevalence of methylphenidate (MPH) usage among medical 
students, to emphasize pharmacological effects and adverse reactions.  
Materials and methods. A self-administered, anonymous questionnaire was distributed in 
online and sheet forms to students of the ungraduated medical programme. The literature 
